Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives

References

• Organization WH. Global influenza strategy 2019–2030. [cited 2019 May 20]. Available from: https://apps.who.int/iris/bitstream/handle/10665/311184/9789241515320-eng.pdf
   Google Scholar
• Hak E, Nordin J, Wei F, et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis. 2002 Aug 15;35(4):370–377.
   PubMed Web of Science ®Google Scholar
• Pebody R, Warburton F, Ellis J, et al. End-of-season influenza vaccine effectiveness in adults and children, United Kingdom, 2016/17. Euro Surveill. 2017 Nov;22(44):17-00306.
   Google Scholar
• Hayden FG, Shindo N. Influenza virus polymerase inhibitors in clinical development. Curr Opin Infect Dis. 2019 Apr;32(2):176–186.
   PubMed Web of Science ®Google Scholar
• Dong G, Peng C, Luo J, et al. Adamantane-resistant influenza a viruses in the world (1902–2013): frequency and distribution of M2 gene mutations. PLoS One. 2015;10(3):e0119115.
   PubMed Web of Science ®Google Scholar
• Jefferson T, Demicheli V, Di Pietrantonj C, et al. Amantadine and rimantadine for influenza A in adults, cochrane database. Syst Rev. 2006 Apr 19;2:CD001169.
   Google Scholar
• McKimm-Breschkin JL, Jiang S, Hui DS, et al. Prevention and treatment of respiratory viral infections: presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV antiviral group conference. Antiviral Res. 2018;149:118–142.
   PubMed Web of Science ®Google Scholar
• Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003 Jul 28;163(14):1667–1672.
   PubMed Web of Science ®Google Scholar
• Excellence NIfHaC. Amantadine, oseltamivir and zanamivir for the treatment of influenza (technology appraisal guidance). [cited 2018 Dec 26]. Available from: www.nice.org.uk/Guidance/ta168
   Google Scholar
• Matrosovich MN, Matrosovich TY, Gray T, et al. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol. 2004 Nov;78(22):12665–12667.
   PubMed Web of Science ®Google Scholar
• Yang X, Steukers L, Forier K, et al. A beneficiary role for neuraminidase in influenza virus penetration through the respiratory mucus. PLoS One. 2014;9(10):e110026.
   PubMed Web of Science ®Google Scholar
• Chand P, Kotian PL, Dehghani A, et al. Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity. J Med Chem. 2001 Dec 6;44(25):4379–4392.
   PubMed Web of Science ®Google Scholar
• Krol E, Rychlowska M, Szewczyk B. Antivirals–current trends in fighting influenza. Acta Biochim Pol. 2014;61(3):495–504.
   PubMed Web of Science ®Google Scholar
• Pizzorno A, Bouhy X, Abed Y, et al. Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. J Infect Dis. 2011 Jan 1;203(1):25–31.
   PubMed Web of Science ®Google Scholar
• Cass LM, Efthymiopoulos C, Bye A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet. 1999;36(Suppl 1):1–11.
   PubMed Web of Science ®Google Scholar
• Agency EM. Summary on compassionate use for IV Zanamivir. [cited 2019 May 24]. Available from: https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-iv-zanamivir-rev-1_en.pdf
   Google Scholar
• Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical practice guidelines by the infectious diseases society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis. 2018 Dec 19;68(6):e1-e47.
   Google Scholar
• Marty FM, Man CY, van der Horst C, et al. Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II study. J Infect Dis. 2014 Feb 15;209(4):542–550.
   PubMed Web of Science ®Google Scholar
• Cleary PR, Crofts J, Parry-Ford F, et al. Characteristics and mortality of severe influenza cases treated with parenteral aqueous zanamivir, United Kingdom, october 2009 to january 2011. Influenza Other Respir Viruses. 2019 Jan;13(1):44–53.
   PubMed Web of Science ®Google Scholar
• McLaughlin MM, Skoglund EW, Ison MG. Peramivir: an intravenous neuraminidase inhibitor. Expert Opin Pharmacother. 2015;16(12):1889–1900.
   PubMed Web of Science ®Google Scholar
• De Clercq E, Li G. Approved antiviral drugs over the past 50 years. Clin Microbiol Rev. 2016 Jul;29(3):695–747.
   PubMed Web of Science ®Google Scholar
• Koyama K, Takahashi M, Oitate M, et al. CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract. Antimicrob Agents Chemother. 2009 Nov;53(11):4845–4851.
   PubMed Web of Science ®Google Scholar
• Davies BE. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J Antimicrob Chemother. 2010 Apr;65(Suppl 2):ii5–ii10.
   PubMed Web of Science ®Google Scholar
• Hoffmann G, Funk C, Fowler S, et al. Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. Antimicrob Agents Chemother. 2009 Nov;53(11):4753–4761.
   PubMed Web of Science ®Google Scholar
• Le QM, Wertheim HF, Tran ND, et al. A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. N Engl J Med. 2010 Jan 7;362(1):86–87.
   PubMed Web of Science ®Google Scholar
• Administration FaD. Tamiflu package insert, oserltamivir phosphate. [cited 2019 May 31]. Available from: https://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/ucm147992.pdf
   Google Scholar
• Dutkowski R, Thakrar B, Froehlich E, et al. Safety and pharmacology of oseltamivir in clinical use. Drug Saf. 2003;26(11):787–801.
   PubMed Web of Science ®Google Scholar
• Peng AW, Milleri S, Stein DS. Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation. Antimicrob Agents Chemother. 2000 Jul;44(7):1974–1976.
   PubMed Web of Science ®Google Scholar
• Marty FM, Vidal-Puigserver J, Clark C, et al. Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial. Lancet Respir Med. 2017 Feb;5(2):135–146.
   PubMed Web of Science ®Google Scholar
• Ison MG. Clinical use of approved influenza antivirals: therapy and prophylaxis. Influenza Other Respir Viruses. 2013 Jan;7(Suppl 1):7–13.
   PubMed Web of Science ®Google Scholar
• Ison MG. Influenza, including the novel H1N1, in organ transplant patients. Curr Opin Infect Dis. 2010 Aug;23(4):365–373.
   PubMed Web of Science ®Google Scholar
• Samson M, Pizzorno A, Abed Y, et al. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res. 2013 May;98(2):174–185.
   PubMed Web of Science ®Google Scholar
• FDA. Food and drug administration emergency use authorization fact sheet for heath care providers
   Google Scholar
• Watanabe A, Chang SC, Kim MJ, et al. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial. Clin Infect Dis. 2010 Nov 15;51(10):1167–1175.
   PubMed Web of Science ®Google Scholar
• Administration FaD. Relenza package insert, zanamivir for inhalation. [cited 2019 May 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021036Orig1s008.pdf
   Google Scholar
• Administration USFAD. Questions and answers for health care providers: renal dosing and administration recommendations for peramivir IV. [cited 2019 May 01]. Available from: https://www.fda.gov/media/77913/download
   Google Scholar
• Ishizuka H, Yoshiba S, Okabe H, et al. Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers. J Clin Pharmacol. 2010 Nov;50(11):1319–1329.
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US oral neuraminidase study group. Jama. 2000 Feb 23;283(8):1016–1024.
   PubMed Web of Science ®Google Scholar
• No authors listed.Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (management of influenza in the Southern hemisphere trialists) study group. Lancet. 1998 Dec 12;352(9144):1877–1881.
   PubMed Web of Science ®Google Scholar
• Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 influenza study group. N Engl J Med. 1997 Sep 25;337(13):874–880.
   PubMed Web of Science ®Google Scholar
• Kohno S, Yen MY, Cheong HJ, et al. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother. 2011 Nov;55(11):5267–5276.
   PubMed Web of Science ®Google Scholar
• Wu JT, Leung GM, Lipsitch M, et al. Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy. PLoS Med. 2009 May 19;6(5):e1000085.
   PubMed Web of Science ®Google Scholar
• Smee DF, Hurst BL, Wong MH, et al. Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice. Antiviral Res. 2010 Oct;88(1):38–44.
   PubMed Web of Science ®Google Scholar
• Duval X, van der Werf S, Blanchon T, et al. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med. 2010 Nov 2;7(11):e1000362.
   PubMed Web of Science ®Google Scholar
• Escuret V, Cornu C, Boutitie F, et al. Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections. Antiviral Res. 2012 Nov;96(2):130–137.
   PubMed Web of Science ®Google Scholar
• Beigel JH, Bao Y, Beeler J, et al. Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial. Lancet Infect Dis. 2017 Dec;17(12):1255–1265.
   PubMed Web of Science ®Google Scholar
• Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med. 1999 Oct 28;341(18):1336–1343.
   PubMed Web of Science ®Google Scholar
• Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families. Zanamivir family study group. N Engl J Med. 2000 Nov 2;343(18):1282–1289.
   PubMed Web of Science ®Google Scholar
• Monto AS, Pichichero ME, Blanckenberg SJ, et al. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis. 2002 Dec 1;186(11):1582–1588.
   PubMed Web of Science ®Google Scholar
• Toovey S, Rayner C, Prinssen E, et al. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf. 2008;31(12):1097–1114.
   PubMed Web of Science ®Google Scholar
• Prevention CfDCa, Updated Interim Recommendations for the Use of Antiviral Medications in the Treatment and Prevention of Influenza for the 2009–2010 Season
   Google Scholar
• Leung SSY, Parumasivam T, Tang P, et al. A proof-of-principle setup for delivery of Relenza((R)) (zanamivir) inhalation powder to intubated patients. J Aerosol Med Pulm Drug Deliv. 2016 Feb;29(1):30–35.
   PubMed Web of Science ®Google Scholar
• Kiatboonsri S, Kiatboonsri C, Theerawit P. Fatal respiratory events caused by zanamivir nebulization. Clin Infect Dis. 2010 Feb 15;50(4):620.
   PubMed Web of Science ®Google Scholar
• Administration FaD. Safety alert for Relenza (zanamivir) inhalation powder. [cited 2019 May 19]. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm186081.htm
   Google Scholar
• Kohno S, Kida H, Mizuguchi M, et al. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother. 2010 Nov;54(11):4568–4574.
   PubMed Web of Science ®Google Scholar
• Alpivab, INN-peramivir, E. M. Agency, 2018.
   Google Scholar
• McAuley JL, Gilbertson BP, Trifkovic S, et al. Influenza virus neuraminidase structure and functions. Front Microbiol. 2019;10:39.
   PubMed Web of Science ®Google Scholar
• Nguyen HT, Fry AM, Gubareva LV. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir Ther. 2012;17(1 Pt B):159–173.
   PubMed Web of Science ®Google Scholar
• Hurt AC, Chotpitayasunondh T, Cox NJ, et al. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis. 2012 Mar;12(3):240–248.
   PubMed Web of Science ®Google Scholar
• Vavricka CJ, Li Q, Wu Y, et al. Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition. PLoS Pathog. 2011 Oct;7(10):e1002249.
   PubMed Web of Science ®Google Scholar
• Sleeman K, Sheu TG, Moore Z, et al. Influenza B viruses with mutation in the neuraminidase active site, North Carolina, USA, 2010–11. Emerg Infect Dis. 2011 Nov;17(11):2043–2046.
   PubMed Web of Science ®Google Scholar
• Li TC, Chan MC, Lee N. Clinical implications of antiviral resistance in influenza. Viruses. 2015 Sep 14;7(9):4929–4944.
   PubMed Web of Science ®Google Scholar
• Gubareva LV, Besselaar TG, Daniels RS, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015–2016. Antiviral Res. 2017;146:12–20.
   PubMed Web of Science ®Google Scholar
• Lina B, Boucher C, Osterhaus A, et al. Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the influenza resistance information study. Influenza Other Respir Viruses. 2018 Mar;12(2):267–278.
   PubMed Web of Science ®Google Scholar
• Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science. 2009 Jul 10;325(5937):197–201.
   PubMed Web of Science ®Google Scholar
• Calatayud L, Lackenby A, Reynolds A, et al. Oseltamivir-resistant pandemic (H1N1) 2009 virus infection in England and Scotland, 2009–2010. Emerg Infect Dis. 2011 Oct;17(10):1807–1815.
   PubMed Web of Science ®Google Scholar
• Kelso A, Hurt AC. The ongoing battle against influenza: drug-resistant influenza viruses: why fitness matters. Nat Med. 2012 Oct;18(10):1470–1471.
   PubMed Web of Science ®Google Scholar
• Baz M, Abed Y, Papenburg J, et al. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N Engl J Med. 2009 Dec 3;361(23):2296–2297.
   PubMed Web of Science ®Google Scholar
• Lackenby A, Thompson CI, Democratis J. The potential impact of neuraminidase inhibitor resistant influenza. Curr Opin Infect Dis. 2008 Dec;21(6):626–638.
   PubMed Web of Science ®Google Scholar
• Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza — recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2011 Jan 21;60(1):1–24.
   PubMedGoogle Scholar
• Arya V, Carter WW, Robertson SM. The role of clinical pharmacology in supporting the emergency use authorization of an unapproved anti-influenza drugperamivir. Clin Pharmacol Ther. 2010 Nov;88(5):587–589.
   PubMed Web of Science ®Google Scholar
• Lee N, Chan PK, Wong CK, et al. Viral clearance and inflammatory response patterns in adults hospitalized for pandemic 2009 influenza A(H1N1) virus pneumonia. Antivir Ther. 2011;16(2):237–247.
   PubMed Web of Science ®Google Scholar
• Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical practice guidelines by the infectious diseases society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenzaa. Clin Infect Dis. 2019 Mar 5;68(6):e1–e47.
   PubMed Web of Science ®Google Scholar
• Pillai VC, Han K, Beigi RH, et al. Population pharmacokinetics of oseltamivir in non-pregnant and pregnant women. Br J Clin Pharmacol. 2015 Nov;80(5):1042–1050.
   PubMed Web of Science ®Google Scholar
• South East Asia Infectious Disease Clinical Research N. Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial. Bmj. 2013 May 30;346:f3039.
   PubMed Web of Science ®Google Scholar
• Prevention CfDCa. Influenza antiviral medications: summary for clinicians. [cited 2018 Dec 30]. Available from: https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm
   Google Scholar
• Ikematsu H, Kawai N. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. Expert Rev Anti Infect Ther. 2011 Oct;9(10):851–857.
   PubMed Web of Science ®Google Scholar
• Appiah GD, Chaves SS, Kirley PD, et al. Increased antiviral treatment among hospitalized children and adults with laboratory-confirmed influenza, 2010–2015. Clin Infect Dis. 2017 Feb 1;64(3):364–367.
   PubMed Web of Science ®Google Scholar
• Ison MG. Contemporary influenza diagnostics: renewed focus on testing patients. Ann Intern Med. 2017 Sep 19;167(6):438–439.
   PubMed Web of Science ®Google Scholar
• (2017 Aug). Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza- review of recent systematic reviews and meta-analyses.
   Google Scholar
• Wang CH, Chung FT, Lin SM, et al. Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure. Crit Care Med. 2014 Feb;42(2):313–321.
   PubMed Web of Science ®Google Scholar